Elizabeth A. Musgrove

St Vincent's Hospital — Australia

Medicine · Health Sciences

84h-index41.3kcitations292works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer-related Molecular Pathways(89), Estrogen and related hormone effects(61), Cancer Genomics and Diagnostics(44), Advanced Breast Cancer Therapies(38), Epigenetics and DNA Methylation(31)

Publications239 total

Current oral care practices in an acute aged care setting: An Australian metropolitan hospital perspective
International Journal of Speech-Language Pathology·2024
Supplementary Figure 2 from BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer
2023Open Access
Supplementary Figure 2 from Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells
2023Open Access
Data from BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer
2023Open Access
Supplementary Figure 6 from BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer
2023Open Access
Supplementary Figure 3 from Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells
2023Open Access
Supplementary Figure 3 from BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer
2023Open Access
Supplementary Methods, Figure Legends and Tables 1 - 2 from Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells
2023Open Access
Supplementary Materials and Methods from BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer
2023Open Access
Supplementary Figure 1 from Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells
2023Open Access
Supplementary Figure 2 from Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells
2023Open Access
Supplementary Figure 4 from BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer
2023Open Access
Supplementary Figure 3 from BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer
2023Open Access
Supplementary Figure 5 from BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer
2023Open Access
Supplementary Figure Legends from BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer
2023Open Access
Supplementary Methods, Figure Legends and Tables 1 - 2 from Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells
2023Open Access
Supplementary Figure 1 from BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer
2023Open Access
Data from Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells
2023Open Access
Supplementary Figure 1 from Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells
2023Open Access
Data from Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells
2023Open Access
page 1 of 12Next →

Frequent Co-authors

Robert L. Sutherland(23), David K. Chang(13), Andrew V. Biankin(11), Amber L. Johns(10), Marina Pajic(10), Marc D. Jones(9), Nigel B. Jamieson(9), R. Sutherland(9), Venessa Chin(8), Lorraine A. Chantrill(8), Jeremy L. Humphris(8), Christopher J. Scarlett(8), Peter J. Bailey(7), Craig Nourse(7), Jianmin Wu(7), Mark Pinese(7), Mark J. Cowley(7), Angela Chou(7), Ilse Rooman(7), Jaswinder S. Samra(7)